Agnieszka Sitek-Druzd

Warsaw, MZ, Poland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 36 publications

Corrigendum to "Obinutuzumab induction and maintenance in patients with Waldenström macroglobulinaemia: an open-label, single-arm phase 2 study" EClinicalMedicine. 2025 Jul 25:86:103383.

Corrigendum to "Obinutuzumab induction and maintenance in patients with Waldenström macroglobulinaemia: an open-label, single-arm phase 2 study" EClinicalMedicine. 2025 Jul 25:86:103383.

Journal: EClinicalMedicine

Published: April 21, 2026

Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial.

Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial.

Journal: The Lancet. Haematology

Published: November 21, 2025

Daratumumab or active observation for asymptomatic biochemical relapse in patients with multiple myeloma.

Daratumumab or active observation for asymptomatic biochemical relapse in patients with multiple myeloma.

Journal: British journal of haematology

Published: October 09, 2025

The long-term efficacy and safety of high-dose chemotherapy with autologous stem cell transplantation in the treatment of primary central nervous system lymphoma: A real-world report from the Polish Lymphoma Research Group.

The long-term efficacy and safety of high-dose chemotherapy with autologous stem cell transplantation in the treatment of primary central nervous system lymphoma: A real-world report from the Polish Lymphoma Research Group.

Journal: European journal of cancer (Oxford, England : 1990)

Published: August 16, 2025

Obinutuzumab induction and maintenance in patients with Waldenström macroglobulinaemia: an open-label, single-arm phase 2 study.

Obinutuzumab induction and maintenance in patients with Waldenström macroglobulinaemia: an open-label, single-arm phase 2 study.

Journal: EClinicalMedicine

Published: March 14, 2025

Health-related quality of life in patients with multiple myeloma treated in the phase 3 ATLAS trial of post-transplant maintenance with carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone.

Health-related quality of life in patients with multiple myeloma treated in the phase 3 ATLAS trial of post-transplant maintenance with carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone.

Journal: Polish archives of internal medicine

Published: May 15, 2024

Mass spectrometry-based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma.

Mass spectrometry-based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma.

Journal: Blood

Published: February 13, 2024

Therapeutic adherence and assessment of satisfaction patients with multiple myeloma treated with immunomodulatory drugs in a "real-world" study: Experiences of the Polish Myeloma Group.

Therapeutic adherence and assessment of satisfaction patients with multiple myeloma treated with immunomodulatory drugs in a "real-world" study: Experiences of the Polish Myeloma Group.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: September 20, 2023

Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial.

Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial.

Journal: British journal of haematology

Published: June 28, 2023

Identification of novel genetic loci for risk of multiple myeloma by functional annotation.

Identification of novel genetic loci for risk of multiple myeloma by functional annotation.

Journal: Leukemia

Published: March 08, 2023

Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma: A Meta-Analysis of Three Large Cohorts and Functional Characterization.

Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma: A Meta-Analysis of Three Large Cohorts and Functional Characterization.

Journal: International journal of molecular sciences

Published: March 04, 2023

A Stepwise Screening Protocol for Multiple Myeloma.

A Stepwise Screening Protocol for Multiple Myeloma.

Journal: Journal of clinical medicine

Published: November 27, 2022

Showing 1-12 of 36

Last Updated: 09/26/2026